Author:
Liu Feng,Liu ShiYing,Liu Yan,Han DaXiong,Jiang YuYang,Cao ShengLi,Zhao YuFen
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Marriott J H, Neidle S, Matusiak Z, et al. Chemoenzymatic preparation of the novel antifolate thymidylate synthase inhibitor N-(4-{N-[(6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}-benzoyl)-L-glutamic acid and its glutamyl cleavage product. J Chem Soc, Perkin Trans, 1999, 1: 1495
2. Kelland L R, Kimbell R, Hardcastle A, et al. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer, 1995, 31A: 981–986
3. Jackman A L, Farrugia D C, Gibson W, et al. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer, 1995, 31A: 1277–1282
4. Peters G J, Smitskamp-Wilms E, Smid K, et al. Determinants of activity of the antifolate thymidylate synthase inhibitors tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res, 1999, 59: 5529–5535
5. Lewis N L, Scher R, Gallo J M, et al. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemoth Pharm, 2002, 50: 257–265
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献